Spherix’s coverage of the lupus nephritis market combines insights from nephrologists and rheumatologists to provide coverage on both current, as well as evolving, treatment paradigms, as patients with high unmet needs begin to see new solutions. Market trending reports coupled with patient chart audits and launch trackers for exciting new products provide unique and invaluable insights into this expanding market.
Exploring the patient journey
Lupus Nephritis (US) - annual, n=1,000 patient charts
Prepping for the pipeline
Lupus Nephritis (US) - annual, n=100 patient charts
Benchmarking new brand performance
Benlysta (GSK) and Voclosporin (Aurinia) in Lupus Nephritis (US)*
*Pending approvals and launch